Neuropharmacology & Neurotherapeutics
Pramipexole is approved for the treatment of early Parkinson disease as monotherapy and as an adjunct to levodopa in advanced stages of the disease. It is also approved for the treatment of restless legs syndrome. Patients with advanced Parkinson disease who have blood pressure problems should use pramipexole with care. Additionally, pramipexole is excreted through the kidneys, and patients with kidney disease may require dosage adjustment.
Sep. 06, 2020